Daniel Andrés Nieva-Posso, Valeria Perea Ocampo, Daniel Alfonso Nieva Posso, Herney Andrés García-Perdomo
{"title":"甲状腺疾病与患前列腺癌风险之间的关系：一项系统综述和荟萃分析。","authors":"Daniel Andrés Nieva-Posso, Valeria Perea Ocampo, Daniel Alfonso Nieva Posso, Herney Andrés García-Perdomo","doi":"10.1177/03915603251336971","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the association between thyroid disorders and the Risk of developing prostate cancer.</p><p><strong>Methods: </strong>We conducted this review following the recommendations of the Cochrane Collaboration and the PRISMA Statement. From the moment to the present, we have conducted a search strategy using MEDLINE, WEB OF SCIENCE, and GOOGLE SCHOLAR. We included cohort and case-control studies that examined the relationship between thyroid disorders and the Risk of developing prostate cancer. We assessed the Risk of bias using the Newcastle Ottawa Quality Assessment scale. Meta-analysis was conducted in Review Manager 5.4.1 (Revman<sup>®</sup>).</p><p><strong>Results: </strong>We included nine studies in the analysis. The studies included were classified into two groups: those that studied hypothyroidism and those that studied hyperthyroidism. The results showed no association between thyroid abnormalities and prostate cancer risk, with an HR of 1.05 (95% CI: 0.90-1.22). Hyperthyroidism also showed no association with an HR 1.64 (95% CI: 1.00-2.69), characterized by increased serum T4 and decreased TSH. There was also no significant association with hypothyroidism, with an HR of 0.85 (95% CI: 0.67-1.10).</p><p><strong>Conclusion: </strong>Thyroid disorders were not associated with the Risk of developing prostate cancer.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251336971"},"PeriodicalIF":0.8000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between thyroid disorders and the Risk of developing prostate cancer: A systematic review and meta-analysis.\",\"authors\":\"Daniel Andrés Nieva-Posso, Valeria Perea Ocampo, Daniel Alfonso Nieva Posso, Herney Andrés García-Perdomo\",\"doi\":\"10.1177/03915603251336971\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To determine the association between thyroid disorders and the Risk of developing prostate cancer.</p><p><strong>Methods: </strong>We conducted this review following the recommendations of the Cochrane Collaboration and the PRISMA Statement. From the moment to the present, we have conducted a search strategy using MEDLINE, WEB OF SCIENCE, and GOOGLE SCHOLAR. We included cohort and case-control studies that examined the relationship between thyroid disorders and the Risk of developing prostate cancer. We assessed the Risk of bias using the Newcastle Ottawa Quality Assessment scale. Meta-analysis was conducted in Review Manager 5.4.1 (Revman<sup>®</sup>).</p><p><strong>Results: </strong>We included nine studies in the analysis. The studies included were classified into two groups: those that studied hypothyroidism and those that studied hyperthyroidism. The results showed no association between thyroid abnormalities and prostate cancer risk, with an HR of 1.05 (95% CI: 0.90-1.22). Hyperthyroidism also showed no association with an HR 1.64 (95% CI: 1.00-2.69), characterized by increased serum T4 and decreased TSH. There was also no significant association with hypothyroidism, with an HR of 0.85 (95% CI: 0.67-1.10).</p><p><strong>Conclusion: </strong>Thyroid disorders were not associated with the Risk of developing prostate cancer.</p>\",\"PeriodicalId\":23574,\"journal\":{\"name\":\"Urologia Journal\",\"volume\":\" \",\"pages\":\"3915603251336971\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologia Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/03915603251336971\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/03915603251336971","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：探讨甲状腺功能障碍与前列腺癌发病风险的关系。方法：我们按照Cochrane协作和PRISMA声明的建议进行了本综述。从现在开始，我们使用MEDLINE， WEB OF SCIENCE和b谷歌SCHOLAR进行了搜索策略。我们纳入了队列研究和病例对照研究，这些研究检查了甲状腺疾病与患前列腺癌风险之间的关系。我们使用纽卡斯尔渥太华质量评估量表评估偏倚风险。meta分析在Review Manager 5.4.1 （Revman®）中进行。结果：我们纳入了9项研究。纳入的研究分为两组：一组研究甲状腺功能减退症，另一组研究甲状腺功能亢进症。结果显示甲状腺异常和前列腺癌风险之间没有关联，风险比为1.05 （95% CI: 0.90-1.22）。甲状腺机能亢进也显示与HR 1.64 （95% CI: 1.00-2.69）无关，其特征是血清T4升高，TSH降低。与甲状腺功能减退也无显著相关性，风险比为0.85 （95% CI: 0.67-1.10）。结论：甲状腺疾病与前列腺癌的发生风险无关。
Association between thyroid disorders and the Risk of developing prostate cancer: A systematic review and meta-analysis.
Objective: To determine the association between thyroid disorders and the Risk of developing prostate cancer.
Methods: We conducted this review following the recommendations of the Cochrane Collaboration and the PRISMA Statement. From the moment to the present, we have conducted a search strategy using MEDLINE, WEB OF SCIENCE, and GOOGLE SCHOLAR. We included cohort and case-control studies that examined the relationship between thyroid disorders and the Risk of developing prostate cancer. We assessed the Risk of bias using the Newcastle Ottawa Quality Assessment scale. Meta-analysis was conducted in Review Manager 5.4.1 (Revman®).
Results: We included nine studies in the analysis. The studies included were classified into two groups: those that studied hypothyroidism and those that studied hyperthyroidism. The results showed no association between thyroid abnormalities and prostate cancer risk, with an HR of 1.05 (95% CI: 0.90-1.22). Hyperthyroidism also showed no association with an HR 1.64 (95% CI: 1.00-2.69), characterized by increased serum T4 and decreased TSH. There was also no significant association with hypothyroidism, with an HR of 0.85 (95% CI: 0.67-1.10).
Conclusion: Thyroid disorders were not associated with the Risk of developing prostate cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
